Stay updated with breaking news from Global Utilization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dual antiplatelet therapy initiated up to 72 hours post-stroke cuts the risk for recurrent stroke but comes with increased bleeding risk, new data from the INSPIRES trial showed.
Researchers have found that ticagrelor-aspirin, compared with clopidogrel-aspirin, is effective and safe for preventing recurrent stroke.
Clinical trials have become too costly and burdensome and it's time to reinvent how they are conducted, leading cardiology societies say in a joint opinion.
Ticagrelor alone decreases risk for bleeding in patients at high risk for ischemic or bleeding events who are receiving PCI.